Our Science
OUR SCIENCE
Congress Presentations
This section includes posters and presentations related to Arvinas’ PROTAC science, discovery compounds, and clinical-stage assets presented at scientific congresses in the past three years.
SABCS 2023 | San Antonio, TX
Dec 5 - 9, 2023
Poster
Updated Results From VERITAC Evaluating Vepdegestrant, a PROteolysis Targeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in ER–Positive/Human Epidermal Growth Factor Receptor 2 (HER2)–Negative Advanced Breast CancerSABCS 2023 | San Antonio, TX
Dec 5 - 9, 2023
Poster
TACTIVE-U: Phase 1b/2 Umbrella Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Combined With Other Anticancer Treatments in ER-Positive Advanced or Metastatic Breast CancerSABCS 2023 | San Antonio, TX
Dec 5 - 9, 2023
Poster
VERITAC-2: A Phase 3 Study of Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, vs Fulvestrant in ER Positive/Human Epidermal Growth Factor Receptor 2 (HER2) Negative Advanced Breast CancerSABCS 2023 | San Antonio, TX
Dec 5 - 9, 2023
Poster
VERITAC-3: A Randomized Phase 3 Study, With a Lead in, of First Line Vepdegestrant + Palbociclib vs Letrozole + Palbociclib in Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative Advanced Breast CancerSABCS 2023 | San Antonio, TX
Dec 5 - 9, 2023
Poster
Leveraging a Pharmacokinetic /Pharmacodynamic (PK/PD) Model to Guide Dose Optimization of Palbociclib in Combination With VepdegestrantESMO-ASIA 2023 | Singapore
Dec 1 - 3, 2023
Poster
Safety and Pharmacokinetics (PK) of Vepdegestrant in Japanese Patients With Estrogen Receptor (ER)+/Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Breast Cancer: Results From a Japanese Phase 1 StudyESMO-ASIA 2023 | Singapore
Dec 1 - 3, 2023
Poster
Global Phase 3 Studies Evaluating Vepdegestrant in Estrogen Receptor (ER)+/Human Epidermal Growth Factor Receptor 2 (HER2) Advanced Breast Cancer: VERITAC-2 and VERITAC-3ESMO 2023 | Madrid, Spain
Oct 20 - 24, 2023
Poster
Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor Degrader, in Estrogen Receptor+/Human Epidermal Growth Factor Receptor 2-Advanced Breast Cancer: Update of Dose Escalation Results From a Phase 1/2 TrialESMO 2023 | Madrid, Spain
Oct 20 - 24, 2023